Increased concentration of sialidases by HeLa cells might influence the cytotoxic ability of NK cells

Taiwanese Journal of Obstetrics and Gynecology

Volumn 51, Issue 2, 2012, Pages 192-198

  Lee, Wen Chi ^a,b   Lee, Wen Ling ^c,d   Shyong, Wen Yuann ^a,b   Yang, Ling Wei ^a,b   Ko, Min Chun ^a,b   Sheu, Bor Ching ^e   Edmond Hsieh, Shie Liang ^a,b   Wang, Peng Hui ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^d ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cervical cancer cell line; Cytotoxicity; Natural killer cell; Neuraminidase; Neuraminidase inhibitor; Sialidase

Indexed keywords

SIALIDASE; SIALIDASE INHIBITOR;

ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; NATURAL KILLER CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HELA CELLS; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; NEURAMINIDASE; SUGAR ACIDS;

EID: 84863877180     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2012.04.005     Document Type: Article

References (24)

1. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006, 16:412-418.
2. Falco M., Biassoni R., Bottino C., Vitale M., Sivori S., Augugliaro R., et al. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Exp Med 1999, 190:793-801.
3. Costello R.T. How to restore normal innate antitumor immunity in acute leukemia?. Leuk Res 2009, 33:613.
4. Weng S.L., Chang S.J., Cheng Y.C., Wang H.Y., Wang T.Y., Chang M.D.T., et al. Comparative transcriptome analysis reveals a fetal origin for mesenchymal stem cells and novel fetal surface antigens for noninvasive prenatal diagnosis. Taiwan J Obstet Gynecol 2011, 50:447-457.
5. Münz C., Dao T., Ferlazzo G., de Cos M.A., Goodman K., Young J.W. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005, 105:266-273.
6. Saito M., Hagita H., Iwabuchi Y., Fujii I., Ikeda L., Ito M. Fluorescent cytochemical detection of sialidase activity using 5-bromo-4-chloroindol-3-yl-α-D-N-acetylneuraminic acid as the substrate. Histochem Cell Biol 2002, 117:453-458.
7. Suzuki T., Takahashi T., Guo C.T., Hidari K.I.P.J., Miyamoto D., Goto H., et al. Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. J Virol 2005, 78:11705-11715.
8. Tsui K.H., Wang P.H., Chen C.K., Chen Y.J., Chiou S.H., Sung Y.J., et al. Non-classical estrogen receptors action on human dermal fibroblasts. Taiwan J Obstet Gynecol 2011, 50:474-478.
9. Lehrnbecher T., Koehl U., Wittekindt B., Bochennek K., Tramsen L., Klingebiel T., et al. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol 2008, 9:269-278.
10. Miyagi T. Aberrant expression of sialidase and cancer progression. Proc Jpn Acad Ser B Phys Biol Sci 2008, 84:407-418.
11. Lee B.K., Kim M.J., Jang H.S., Lee H.R., Ahn K.M., Lee J.H., et al. A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line. In Vivo 2008, 22:593-597.
12. Miyagi T., Wada T., Yamaguchi K. Roles of plasma membrane-associated sialidase NEU3 in human cancers. Biochim Biophys Acta 2008, 1780:532-537.
13. Chang W.W., Yu C.Y., Lin T.W., Wang P.H., Tsai Y.C. Soyasaponin I decreases the expression of α2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. Biochem Biophys Res Commun 2006, 341:614-619.
14. Hsu C.C., Lin T.W., Chang W.W., Wu C.Y., Lo W.H., Wang P.H., et al. Soyasaponin-I modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol 2005, 96:415-422.
15. Imaizumi Y., Higai K., Suzuki C., Azuma Y., Matsumoto K. NKG2D and CD94 bind to multimeric alpha2,3-linked N-acetylneuraminic acid. Biochem Biophys Res Commun 2009, 382:604-608.
16. Nojiri N., Takaku F., Tetsuka T., Saito M. Stimulation of sialidase activity during cell differentiation of human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 1982, 104:1239-1246.
17. Schengrund C.L., Lausch R.N., Rosenberg A. Sialidase activity in transformed cells. J Biol Chem 1973, 248:4424-4428.
18. Saito M., Yu R.K. Possible role of myelin-associated neuraminidase in membrane adhesion. J Neurosci Res 1993, 36:127-132.
19. Kakugawa Y., Wada T., Yamaguchi K., Yamanami H., Ouchi K., Sato I., et al. Up-regulation of plasma membrane associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci USA 2002, 99:10718-10723.
20. Kato K., Shiga K., Yamaguchi K., Hata K., Kobayashi T., Miyazaki K., et al. Plasma-membrane-associated sialidase (NEU3) differentially regulates integrin mediated cell proliferation through laminin- and fibronectin-derived signaling. Biochem J 2006, 394:647-656.
21. Ueno S., Saito S., Wada T., Yamaguchi K., Satoh M., Arai Y., et al. Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes the interleukin-6-induced apoptosis suppression and cell motility. J Biol Chem 2006, 281:7756-7764.
22. Nomura H., Tamada Y., Miyagi T., Suzuki A., Taira M., Suzuki N., et al. Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol Res 2006, 16:289-297.
23. Wada T., Hata K., Yamaguchi K., Shiozaki K., Koseki K., Moriya S., et al. A crucial role of plasma membrane-associated sialidase (NEU3) in the survival of human cancer cells. Oncogene 2007, 26:2483-2490.
24. Lin C.Y., Chuang T.F., Liao K.W., Huang Y.J., Pai C.C., Chu R.M. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett 2008, 272:285-295.